Tohoku University School of Medicine Sendai Miyagi Japan.
Department of Population Health Science and Policy Icahn School of Medicine at Mount Sinai New York NY USA.
J Am Heart Assoc. 2024 Apr 16;13(8):e034506. doi: 10.1161/JAHA.124.034506. Epub 2024 Apr 12.
Clinical practice guidelines (CPGs) offer disease management recommendations based on scientific evidence. However, financial conflicts of interest between CPG developers and the pharmaceutical industry could bias these recommendations, potentially affecting patient care. Proper management of these conflicts of interest is particularly crucial for maintaining the integrity of CPGs. The study aimed to evaluate the extent of financial relationships between the pharmaceutical industry and authors of CPGs for cardiovascular diseases in Japan.
The study analyzed personal payments from the pharmaceutical industry to authors of cardiovascular disease CPGs published by the Japanese Circulation Society from January 2015 to December 2022. Payment data, including speaking, consultancy, and writing fees from 2016 to 2020, were extracted from a publicly available database containing personal payments disclosed by all major pharmaceutical companies. A total of 929 unique authors from 37 eligible Japanese Circulation Society CPGs were identified. Notably, 94.4% of these authors received personal payments from pharmaceutical companies, totaling >US $70.8 million. The mean±SD payment per author was US $76 314±138 663) and the median payment per author was US $20 792 (interquartile range: US $4262-US $76 998) over the 5-year period. Chairs of CPGs received significantly higher payments than other authors. More than 80% of authors in each CPG received personal payments.
The study elucidated that there were considerable financial relationships between pharmaceutical companies and cardiology CPG authors in Japan. This finding deviates from international conflict of interest management policies, suggesting the need for more stringent conflict of interest management strategies by the Japanese Circulation Society to ensure the development of trustworthy and evidence-based CPGs.
临床实践指南（CPGs）基于科学证据提供疾病管理建议。然而，CPG 开发者与制药业之间的财务利益冲突可能会使这些建议产生偏差，从而可能影响患者的护理。适当管理这些利益冲突对于维护 CPG 的完整性尤为重要。本研究旨在评估日本心血管疾病 CPG 作者与制药业之间财务关系的程度。
本研究分析了日本循环学会（Japanese Circulation Society）在 2015 年 1 月至 2022 年 12 月期间发布的心血管疾病 CPG 中制药业向作者支付的个人款项。从一个包含所有主要制药公司披露的个人支付的公开数据库中提取了 2016 年至 2020 年的演讲、咨询和写作费用等支付数据。从 37 项符合条件的日本循环学会 CPG 中确定了 929 位独特的作者。值得注意的是，这些作者中有 94.4%收到了制药公司的个人付款，总额超过 7080 万美元。每位作者的平均支付额为 76314 美元±138663 美元，中位数支付额为每位作者 20792 美元（四分位距：4262 美元至 76998 美元），支付额在 5 年内有所增加。CPG 主席的支付额明显高于其他作者。每个 CPG 中超过 80%的作者都收到了个人付款。
本研究表明，日本制药公司与心脏病学 CPG 作者之间存在相当大的财务关系。这一发现与国际利益冲突管理政策不符，表明日本循环学会需要更严格的利益冲突管理策略，以确保制定值得信赖且基于证据的 CPG。
